Dr Doris Taylor, CEO RegenMedix Consulting LLC, is a dynamic scientist who has made field- changing innovations in regenerative medicine, stem cell profiling, and tissue engineering.

Based on her exceptional ability to reduce these complex topics to simple messages, she is also a highly sought after motivational and keynote speaker nationally and internationally at scientific, corporate, and medical conferences. She currently serves as a consultant in both the regenerative medicine and biotechnology space for government, academia, and industry.

Dr. Taylor helped create the field of cardiovascular regenerative medicine and is widely regarded as a major thought-leader in the field; her mechanistic insights and effective approaches to cardiac repair and replacement are well established and include a number of firsts. At Duke University Medical Center in 1998, she described the first functional repair of injured heart with cells – helping establish cardiovascular regenerative medicine. In 2000 recognizing that cells were heterogeneous and would persist in patients, she began to link individual cardiovascular cell product profiles to patient health and clinical trial outcome – building a capacity to reduce trial size and ask cutting edge questions about the roles of biologic sex, age, and race/ethnicity in cardiovascular regenerative medicine. In 2008, Taylor developed a whole-organ perfusion decellularization method that yielded an acellular solid organ scaffold with vasculature – transforming tissue and organ engineering possibilities. This was so revolutionary it was recognized as one of the “Top 10 Research Advances” by the American Heart Association and Taylor was nominated as one of “100 most influential people in the world” by Time magazine.

In 2009, Taylor co-founded Miromatrix Medical Inc. to commercialize decellularized/ recellularized products. Taylor holds 4 US and 28 international related patents and was recently elected as a senior member of the National Academy of Inventors. She continues to create academic-industry partnerships designed to build regenerative medicine solutions for patients.

Having served on the FDA Cell and Gene Therapy Advisory Panel, the Alliance for Regenerative Medicine Board/Executive Committee, and patient advocacy groups Taylor recognizes the critical importance of communication among scientists, sponsors, patients and regulators. She has been/is involved (inter)nationally on working committees for ESC, NHLBI, AHA, ACC, AABB, FACT, ISHLT, TERMIS, and the Standards Coordinating Body. She co-chairs the Advanced Regenerative Manufacturing Institute (ARMI) Tissue Manufacturing working group, serves on

the ARMI Leadership Advisory Council and is a member of the NIH-wide Regenerative Medicine Information Catalyst that is responsible for designing common data elements for basic, preclinical, and clinical regenerative medicine research funded under the 21st Century Cures Act.

Dr Taylor and her work has been featured by 60 Minutes, CNN, The New York Times, The Wall Street Journal, Associated Press, National Public Radio, and most worldwide media outlets. In 2019, she became a Senior member of the National Academy of Inventors.

Academic Positions

Texas Heart Institute (2012- March 2020):

• Director, Regenerative Medicine Research, Texas Heart Institute (2012- 2020)
• Director, Center for Cell and Organ Biotechnology, Texas A&M University and Texas Heart Institute (2013-2020)
• Director, Biorepository and Sample Profiling Core, NHLBI Cardiovascular Cell Therapy Research Network (CCTRN) and Cardiothoracic Surgery Network (CTSN) (2006-2020)

University of Minnesota Medical School (2003-2012):

• Medtronic Bakken Professor of Integrative Biology and Physiology
• Professor, Department of Medicine
• Director, Center for Cardiovascular Repair

Duke University School of Medicine (1991-2003):

• Assistant to Associate Professor, Department Medicine, Division of Cardiology
• Adjunct appointment, Department of Biomedical Engineering

Industry Roles

• Board member BioHeart Inc, Tampa Florida (2000-2001)
• Co-Founder, Taylor Technologies/Miromatix Medical, Inc., Minneapolis, MN (2008)
• Co-founder/CEO, Stem Cell Security, LLC, Houston, TX (2017)

Other Notable Professional Roles (selected)

• Alliance for Regenerative Manufacturing Institute (ARMI) Leadership Advisory Council (2019-2020)
• AABB Standards Committee member (2018-2019)
• Texas Regenerative Medicine Summit. Scientific Panel, Austin, TX (2018)
• Rice University Baker Institute for Public Policy. “Charlie’s Law: Increased Access to Stem Cell Interventions in Texa” (2017)
• Texas Medical Center Regenerative Medicine Strategy Design Team, Co-chair (2014-

2016)

• National Policy and Science Summit on Women’s Cardiovascular Health, Washington, DC Invited Participant, (2015)
• Co-chair, Sex Bias in Cardiovascular Research Working Group, NIH National Heart, Lung, and Blood Institute (2014)
• Alliance for Regenerative Medicine Board of Directors (2013-2016)
• Alliance for Regenerative Medicine Executive Board (2013-2015)
• S. Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory
• Committee, Center for Biologics Evaluation and Research (2005-2010)
• NIH National Heart, Lung, and Blood Institute Biomedical Imaging Research Opportunities Workshop, Invited Participant, (2005)

Academic Productivity

• Publications: >165 peer-review publications in scientific journals
• Research support: Career total > $25M; PI or co-PI on >20 federal, state, and foundation grants as well as numerous academic, private, and corporate awards
• Commercialization: 4 US Patent Awards, 9 US Patent Applications, 2 Provisional Patent Applications; 28 International Patents
• Education: More than 30 MDs, PhDs, and MD/PhDs have completed predoctoral or postdoctoral research fellowships in D Taylor’s labs at Duke, UMN, or THI
• Service to scientific community: over 300 international, national, regional and local keynote lectures and other scientific presentations